The Case for Universal Varicella Zoster Virus Vaccination

By Danélia Botes

January 11, 2024

Introduction:

The COVID-19 pandemic has monopolised the scientific community’s focus, often at the expense of other crucial health matters. One such overlooked area is the universal vaccination against the varicella zoster virus (VZV). This article explores the reasons behind the delay in its approval and the potential benefits it could bring to public health.

The Delay in Universal VZV Vaccination:

The Joint Committee on Vaccination and Immunisation (JCVI) in the UK, while proactive with COVID-19 immunisations, has been slow to approve the VZV vaccine. This delay has been largely due to the Hope-Simpson hypothesis, which posits that reducing VZV exposure could lead to an increase in herpes zoster (HZ) infections. However, real-world data from countries with a universal VZV immunisation program, such as the USA, contradict these fears.

Private Vaccinations and Epidemiological Concerns:

Despite the JCVI’s hesitance, many UK parents are opting for private VZV vaccinations for their children. The financial burden of children missing school due to chickenpox often outweighs the cost of the vaccine. However, these private vaccinations are not being counted by the UK Health Security Agency (UKHSA) or Department for Health and Social Care (DHSC), leading to an incomplete picture of the disease’s current burden.

The Potential Impact of Universal VZV Vaccination:

The JCVI has recently suggested that the multivalent Hib vaccine could be given at 18 months, freeing up space for the VZV vaccination. This change would require acceptance that the Hope-Simpson hypothesis does not carry significant weight. As a result, they have finally advised that the measles, mumps, and rubella (MMR) vaccines be given with the varicella vaccine at 12 and 18 months.

Remaining Concerns and the Way Forward:

While the risk of febrile seizures when combined with the MMR vaccine is low, some concerns remain. Governmental funding concerns around the cost of vaccination are valid. The indirect economic impact of lost days of work is far more significant. Universal VZV vaccination could also reduce vertical transmission and potentially protect immunosuppressed individuals.

Conclusion:

Our healthcare systems often fall prey to the inverse care law. However, by reducing time off from work for parents, universal VZV vaccination could have the greatest impact on those who earn the least, and potentially improve economic growth in the process.

Reference url

Recent Posts

Pharmacogenetic Screening
            

Pharmacogenetic Screening: A Cost-Effective Strategy in Treating Major Depressive Disorder

🔍 Discover the cost-effectiveness of pharmacogenetic screening in treating Major Depressive Disorder (MDD).
This approach could save costs and improve patient outcomes in the Spanish National Health System. Read more to understand the potential benefits and future implications. 🌐💡
#SyenzaNews #Pharmacogenetics #MajorDepression #CostEffectiveness #HealthcareInnovation

                 

Healthy Ageing Index and Assessment of Age-Related Outcomes

🌟 Healthy Ageing Index and Assessment of Age-Related Outcomes 🌟

📊 Unlocking the Secrets of Healthy Ageing in Singapore! Discover the significance of the Healthy Ageing Index (HAI) in predicting age-related outcomes! Learn how this tool can help promote healthy ageing and improve quality of life. 👵👴

#SyenzaNews #HealthyAgeing #SingaporeHealthcare #AgeingPopulation #HealthOutcomes

Thailand's healthcare system
              

Thailand’s Healthcare System and the Role of HTA: A Model of Universal Health Coverage

Thailand’s healthcare system is a beacon of efficiency and effectiveness. Achieving Universal Health Coverage in 2002, the country has made remarkable strides in health outcomes, despite spending less compared to other upper-middle-income countries.

Learn how Thailand’s use of Health Technology Assessment (HTA) has played a crucial role in this success and the future steps to address current challenges. 🌍💉

#SyenzaNews #Healthcare #UniversalHealthCoverage #HTA #Innovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER




SERVICES

© 2024 Syenza™. All rights reserved.